Core Viewpoint - AIM ImmunoTech Inc. is initiating a clinical study to evaluate the combination of Ampligen and AstraZeneca's FluMist as an intranasal vaccine for influenza, particularly targeting avian influenza strains [1][3]. Group 1: Clinical Study Details - The planned study will follow a previous trial at the University of Alabama-Birmingham (UAB), which demonstrated that Ampligen significantly enhanced the immune response to seasonal influenza variants by over four-fold and induced cross-reactive secretory Immunoglobulin A against avian influenza strains H5N1, H7N9, and H7N3 [2]. - Paul Goepfert, MD, will serve as the Principal Investigator for the study, emphasizing the urgency due to the rising threat of avian influenza [3]. Group 2: Financial and Development Insights - AIM's CEO highlighted the potential for a cost-effective development of the vaccine combination, estimating that it would require no more than $10 million in development costs, significantly less than the billions potentially needed for new mRNA vaccines [4]. - The company is seeking funding for the study through industry or governmental grants, indicating a proactive approach to securing necessary resources [3]. Group 3: Company Background - AIM ImmunoTech Inc. is focused on developing therapeutics for various diseases, including cancers and viral infections, with Ampligen being a key investigational drug that acts as a TLR3 agonist [5].

Core Points - AIM ImmunoTech Inc. has received approval from NYSE American for its plan to regain compliance with minimum stockholders' equity requirements, with a deadline set for June 11, 2026 [1][2] - The company is focused on advancing its oncology and antiviral pipelines while executing its compliance strategy [2] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad-spectrum activity in clinical trials [2]

Core Insights - AIM ImmunoTech Inc. has appointed David Chemerow as an Independent Director to its Board of Directors, effective immediately [1] - Mr. Chemerow has over 40 years of experience in finance, accounting, and operations across various industries, including significant roles at Comscore, Inc. and Rentrak Corporation [2] - The Chairman of AIM's Board, William Mitchell, expressed confidence in Mr. Chemerow's leadership and financial acumen, which are expected to contribute to AIM's mission [6] Company Overview - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for treating cancers, immune disorders, and viral diseases, including COVID-19 [7] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug with broad-spectrum activity in clinical trials for significant health issues [7]

Several subjects who received the highest dose in Phase 1 will also be included in Phase 2OCALA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the Phase 1b/2 clinical trial involving AIM’s Ampligen (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”). Several subjects from Pha ...

Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”)Watch the “What This Means” segment here OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced th ...

Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintatolimod) and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer ("DURIPANC")Watch the "What This Means" segment here OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that AIM CEO ...

OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral ...

OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s antiviral priority development pipeline. AIM has engaged Amarex Clinical Research (“Amarex”), its Clinical Research Organization (“CRO”), with the application and eventual management of a follow-up Investigational New Drug (“IND”) application for the study of a potential ...

OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company's antiviral priority development pipeline. AIM has engaged Amarex Clinical Research ("Amarex"), its Clinical Research Organization ("CRO"), with the application and eventual management of a follow-up Investigational New Drug ("IND") application for the study of a potential avian inf ...

Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting toxicities Enrollment for Phase 2 expected to commence imminently OCALA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced Safety Committee approval to proceed with the Phase 2 portion of the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintato ...